Here at Tampa Cardio, we believe information is power.

Here are the answers you need to keep yourself safe against COVID-19.

 

Latest COVID-19 Variants in the USA (August 2024)

As of August 2024, the United States continues to witness the rapid evolution of COVID-19, with new variants emerging that pose significant challenges for public health. The most prevalent of these are the Omicron variants KP.2, KP.3, and LB.1. Here’s what you need to know about these variants, their characteristics, and how they are being managed.

 

Prevalence of Omicron Variants KP.2, KP.3, and LB.1

The Omicron variant KP.3 is currently the most prevalent, accounting for approximately 37% of new COVID-19 infections. This marks a significant rise from its previous 9.4% share in May. KP.2 follows closely behind, responsible for 24.4% of infections. The LB.1 variant, while less common than KP.3 and KP.2, still comprises a notable 14.9% of cases, although its prevalence has been decreasing.

 

Transmissibility and Immune Evasion

These variants are not only spreading rapidly but also exhibit concerning characteristics in terms of transmissibility and immune evasion.

 

KP.2 and KP.3: Both variants are descendants of the JN.1 variant and possess mutations that allow them to escape vaccine-mediated immunity. KP.2 has a reproductive number 1.22 times higher than its ancestor, indicating higher transmissibility. KP.3 shares similar virological traits with KP.2, making them both formidable in terms of spread and immune evasion.

LB.1: This variant includes an additional mutation (S:S31del) that distinguishes it from KP.2 and KP.3. Preliminary studies suggest that LB.1 might surpass KP.3 in terms of transmissibility, although real-world epidemiological evidence is still being gathered.

Effectiveness of Current Vaccines

Vaccination remains a crucial tool in combating COVID-19, but the effectiveness of current vaccines against these new variants is a mixed bag.

 

JN.1-Specific Vaccines: The JN.1 variant, a precursor to KP.2 and KP.3, has shown substantial resistance to the monovalent XBB.1.5 vaccine. Although the vaccines do still provide some protection, their effectiveness is lower compared to earlier strains.

Bivalent Vaccines: Recent studies have indicated that bivalent vaccines, which target both the ancestral strain and BA.4/BA.5, elicit higher neutralizing antibodies against Omicron subvariants like JN.1. However, the effectiveness against KP.2, KP.3, and LB.1 is not yet fully understood but is expected to be lower due to additional immune evasion properties.

Therapeutics: The Role of Paxlovid

Amidst the evolving variant landscape, Paxlovid has emerged as a beacon of hope. This protease inhibitor targets a part of the virus unrelated to the spike protein, maintaining its effectiveness against variants including JN.1 and the FLiRT family, which encompasses KP.2, KP.3, and LB.1. This makes Paxlovid a crucial treatment option, especially as the virus continues to mutate.

The Importance of Ongoing Vaccination and Research

Despite the challenges posed by these new variants, vaccination remains vital. Updated recommendations advise individuals, especially those aged 65 and older, to receive the latest COVID-19 vaccine. Research is ongoing to develop vaccines that more effectively target the new variants, with a focus on maintaining high levels of immunity within the community.

The Take Away…

The rise of Omicron variants KP.2, KP.3, and LB.1 underscores the dynamic nature of the COVID-19 pandemic. While these variants exhibit higher transmissibility and immune evasion, ongoing vaccination campaigns and treatments like Paxlovid play a critical role in managing their impact. Staying informed about the latest developments and adhering to public health guidelines remains essential for safeguarding public health.

 

For more detailed information and updates, visit the CDC’s COVID Data Tracker and consult with healthcare professionals about the best protective measures.

If you have tested positive for COVID or FLU we do ask that if at all possible you please stay home and stay safe. If you need to make an appointment you have scheduled with us, please call and let us know. We may be able to change you over to a VIRTUAL TELEHEALTH VISIT from the comfort of your home.